Anticipation of immunity for years from the third dose of Covaxin
The Subject Expert Committee of the Drug Controller Regulator General (DGCI) has allowed a third dose trial on Volunteers taking part in the trials of Bharat Biotech's Corona Vaccine Covaxin amidst growing infection of the CoronaVirus across the country. Covaxin is also being used in vaccination campaigns against the coronavirus. The Hyderabad-based company had sent a proposal to the drug controller regulator general for the trial of the third i.e., booster dose after two doses.
Volunteers participating in the study will be given a third dose of Covaxin, six months after the second dose of the vaccine, after approval by a committee of subject experts. For six months after the booster dose is given, India will continue to take biotech updates and information related to their health. Along with this, it will also be seen how much immunity increases in their body and how much help is provided by the new variant.
In the SEC meeting held on 23 March, Bharat Biotech has also been asked to give detailed information about the objectives of the trial and various assessments to be done in the volunteer. Accordingly, the company will also have to submit a revised clinical trial protocol for evaluation.
Bharat Biotech suggested to the government that antibodies to the corona virus would increase for several years after the introduction of the third dose of Covaxin. Along with this, the new variant of Covid-19 will also be saved and new strains will be born by mutation. After this, the expert panel has allowed booster dose.
The Brief. Sign up to receive the top stories you need to know right now.